Zobrazeno 1 - 10
of 121
pro vyhledávání: '"John T. Hunt"'
Autor:
John T. Hunt, Jianing Zeng, Enzo Hamza Kandoussi, Johnni Gullo-Brown, Derrick Maley, Tai-an Lin, Aaron Balog
Tumors can exploit the indoleamine 2,3-dioxygenase 1 (IDO1) pathway to create an immunosuppressive microenvironment. Activated IDO1 metabolizes tryptophan into immunosuppressive kynurenine, leading to suppressed effector T-cell (Teff) proliferation,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16a86db85c1c76e26e999f1e33f880d2
https://doi.org/10.1158/1535-7163.c.6542874
https://doi.org/10.1158/1535-7163.c.6542874
Autor:
John T. Hunt, Jianing Zeng, Enzo Hamza Kandoussi, Johnni Gullo-Brown, Derrick Maley, Tai-an Lin, Aaron Balog
Supplementary Data includes supplementary materials and methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b5166c9a7099cfc5242ffae60fa6adf
https://doi.org/10.1158/1535-7163.22521033
https://doi.org/10.1158/1535-7163.22521033
Autor:
Chiang Yu, Gregory Vite, Simone Oppenheimer, Derek Norris, Harold Malone, Anne Lewin, Daniel Kukral, Bala Krishnan, John T. Hunt, Christine Hilt, Benjamin Henley, Amy Hammell, Ashvinikumar Gavai, Brian Fink, Joseph Fargnoli, Craig Fairchild, Stuart Emanuel, Francis Y. Lee, Tai W. Wong
Supplementary Tables 1-3, Figure Legends 1-6 from Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6f909ef46a03d1570a27d99c5261e2b
https://doi.org/10.1158/1078-0432.22441917.v1
https://doi.org/10.1158/1078-0432.22441917.v1
Autor:
Chiang Yu, Gregory Vite, Simone Oppenheimer, Derek Norris, Harold Malone, Anne Lewin, Daniel Kukral, Bala Krishnan, John T. Hunt, Christine Hilt, Benjamin Henley, Amy Hammell, Ashvinikumar Gavai, Brian Fink, Joseph Fargnoli, Craig Fairchild, Stuart Emanuel, Francis Y. Lee, Tai W. Wong
Purpose: The extensive involvement of the HER kinases in epithelial cancer suggests that kinase inhibitors targeting this receptor family have the potential for broad spectrum antitumor activity. BMS-690514 potently inhibits all three HER kinases, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a33f1ae66761ffc51c82294bcb244134
https://doi.org/10.1158/1078-0432.c.6518787
https://doi.org/10.1158/1078-0432.c.6518787
Autor:
Chiang Yu, Gregory Vite, Simone Oppenheimer, Derek Norris, Harold Malone, Anne Lewin, Daniel Kukral, Bala Krishnan, John T. Hunt, Christine Hilt, Benjamin Henley, Amy Hammell, Ashvinikumar Gavai, Brian Fink, Joseph Fargnoli, Craig Fairchild, Stuart Emanuel, Francis Y. Lee, Tai W. Wong
Supplementary Figures 1-6 from Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10077e61e239f1a813c40834f158a23d
https://doi.org/10.1158/1078-0432.22441920
https://doi.org/10.1158/1078-0432.22441920
Autor:
Jay A. Markwalder, Aaron J. Balog, David K. Williams, Susheel J. Nara, Ratnakar Reddy, Saumya Roy, Yadagiri Kanyaboina, Xin Li, Kathy Johnston, Yi Fan, Hal Lewis, Frank Marsilio, Chunhong Yan, David Critton, John A. Newitt, Sarah C. Traeger, Dauh-Rurng Wu, Maria N. Jure-Kunkel, Lata Jayaraman, Tai-An Lin, Michael W. Sinz, John T. Hunt, Steven P. Seitz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64f0da67b51d6c7282c418d8dbb98887
https://doi.org/10.2139/ssrn.4348735
https://doi.org/10.2139/ssrn.4348735
Autor:
Ching Kim Tye, Chunhong Yan, Sarah C. Traeger, Wayne Vaccaro, Yingru Zhang, Gerry Everlof, Jianqing Li, Henry Yip, Peng Li, John T. Hunt, Michael A. Poss, Gregory D. Vite, Mussari Christopher P, Steven Sheriff, Asoka Ranasinghe, Haiying Zhang, Richard A. Westhouse, Dharmpal S. Dodd, Richard Rampulla, Zheng Yang, Frank Marsilio, Derek J. Norris, Wen-Ching Han, Tram N. Huynh, Yufen Zhao, Patrice Gill, Nirmala Raghavan, Lalgudi S. Harikrishnan, Ashvinikumar V. Gavai, Susan Wee, John S. Tokarski, Dauh-Rurng Wu, Arvind Mathur, Mei-Li Wen, Huiping Zhang, David R. Tortolani, George V. Delucca, Krista Menard, Francis Y. Lee, Claude A. Quesnelle, Dawn Sun, Vijay T. Ahuja, Daniel O'malley, Christine Huang, Muthoni G. Kamau
Publikováno v:
Journal of Medicinal Chemistry. 64:14247-14265
Inhibition of the bromodomain and extra-terminal (BET) family of adaptor proteins is an attractive strategy for targeting transcriptional regulation of key oncogenes, such as c-MYC. Starting with the screening hit 1, a combination of structure-activi
Autor:
Mark Fereshteh, Xiao Zhu, Tai-An Lin, Prabhakar Rajanna, Cherney Emily Charlotte, Aravind Anandam, Xin Li, Derrick Maley, Liping Zhang, Gopal Dhar, Aaron Balog, Robert M. Borzilleri, Johnni Gullo-Brown, T. Thanga Mariappan, Kathy Johnston-Allegretto, Christine Huang, Venkata Murali, John T. Hunt, Sandeep Mahankali, Gregory D. Vite, Lisa M. Kopcho, Shweta Padmanabhan, Sarah C. Traeger
Publikováno v:
ACS Med Chem Lett
[Image: see text] Indoleamine 2,3-dioxygenase 1 (IDO1) has been identified as a target for small-molecule immunotherapy for the treatment of a variety of cancers including renal cell carcinoma and metastatic melanoma. This work focuses on the identif
Autor:
Lisa M. Kopcho, Johnni Gullo-Brown, Shweta Padmanabhan, Pattasseri Shabeerali, Arvind Mathur, Prabhakar Rajanna, Lorell Discenza, Liping Zhang, Zhenqiu Hong, Sarah C. Traeger, Zheng Yang, Cherney Emily Charlotte, Richard Rampulla, David K. Williams, Gopal Dhar, Kimberly A. Foster, James Kempson, Derrick Maley, Mary F. Grubb, Xiao Zhu, Xin Li, Weifang Shan, Robert M. Borzilleri, Diane Delpy, Kevin Stefanski, T. Thanga Mariappan, Gregory D. Vite, Kathy A. Johnston, Audris Huang, Asoka Ranasinghe, Mark Fereshteh, Aravind Anandam, Steven P. Seitz, John T. Hunt, Aaron Balog, Celia D’Arienzo, Anuradha Gupta, Tai-An Lin, Roshan Y. Nimje, Weiwei Guo, Christine Huang, Venkata Murali, Sandeep Mahankali
Publikováno v:
ACS Med Chem Lett
[Image: see text] IDO1 inhibitors have shown promise as immunotherapies for the treatment of a variety of cancers, including metastatic melanoma and renal cell carcinoma. We recently reported the identification of several novel heme-displacing IDO1 i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0f0d7f8a891846e7ad07844b139d549
https://europepmc.org/articles/PMC8274105/
https://europepmc.org/articles/PMC8274105/
Autor:
Steven P. Seitz, Gregory D. Vite, John T. Hunt, Mark Fereshteh, Cherney Emily Charlotte, Joseph Fargnoli, Lorell Discenza, Liping Zhang, Jennifer Brown, Xin Li, Kevin Stefanski, Christine Huang, Asoka Ranasinghe, Lisa M. Kopcho, Xiao Zhu, Aaron Balog, Diane Delpy, Sarah C. Traeger, Jesse Swanson, Mary F. Grubb, Zheng Yang, Theresa Ziemba, Kathy A. Johnston, Kimberly A. Foster, Johnni Gullo-Brown, Celia D’Arienzo, Susheel Jethanand Nara, Robert M. Borzilleri, Derrick Maley, Tai-An Lin
Publikováno v:
ACS Med Chem Lett
[Image: see text] Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-containing dioxygenase enzyme implicated in cancer immune response. This account details the discovery of BMS-986242, a novel IDO1 inhibitor designed for the treatment of a variety of c